Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Encorafenib/Binimetinib Combo Shows Best-In-Class Efficacy in Melanoma

Brandon Scalea
Published: Friday, Aug 31, 2018

Keith Flaherty, MD

Keith T. Flaherty, MD

The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated best-in-class overall survival (OS) and progression-free survival (PFS) in patients with BRAF-mutant metastatic melanoma, according to data presented at the 2018 ASCO Annual Meeting.

-mutated melanoma.

OncLive: Please provide some background to the COLUMBUS trial.

Flaherty: For several years now, we have known that BRAF mutations are a bonafide therapeutic target in melanoma, with about 45% of patients with advanced disease harboring these mutations. We had a first wave of advances around 2010 with vemurafenib and dabrafenib (Tafinlar) coming along and essentially proving that BRAF mutations are a good target. Those drugs ultimately became FDA approved just a couple years later. We began to understand that reactivation of the same pathway in which BRAF resides, the MEK pathway, was a very common theme. There were available MEK inhibitors, which target the downstream pathway from BRAF. It was immediately conceived that if we stitch these 2 drugs together, it would be useful.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication